Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Survey on computer aided decision support for diagnosis of celiac disease Sebastian Hegenbart, Andreas Uhl, Andreas Vécsei Computers in Biology and Medicine.

Systemic treatment of renal cell cancer: A comprehensive review

Volume 18, Issue 6, Pages (September 2015)

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Volume 60, Issue 5, Pages (November 2011)

Novel targets in gastric and esophageal cancer

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

A Royal College of Radiologists National Audit of Radiotherapy in the Treatment of Metastatic Spinal Cord Compression and Implications for the Development.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Acrometastasis from an epidermal-growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma Mau-Ern Poh, Chong-Kin Liam, Jiunn-Liang Tan, Yong-Kek.

Juan W. Valle, Sandrine Faivre, Richard A

GEIS guidelines for gastrointestinal sarcomas (GIST)

Abhimanyu Ghose, Ria Kundu, Tahir Latif

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Pain in cancer survivors; filling in the gaps

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer Peter M.

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma Zoltan Lohinai, MD, Mir Alireza Hoda, MD,

Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case? Monica Giovannini, MD, Carmen.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain.

Targeting T Cell Co-receptors for Cancer Therapy

Volume 26, Issue 2, Pages (February 2018)

Lip edema Journal of the American Academy of Dermatology

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004.

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Clinical courses of patients.

Volume 130, Issue 6, (September 2007)

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Correction Journal of the American College of Surgeons

Erratum Journal of Thoracic Oncology

ED11.01 Systemic Therapy for Advanced Oncogene-Driven NSCLC

Antibiotic De-Escalation

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Volume 17, Issue 2, Pages (February 1950)

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Treatment of Colorectal Cancer

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Volume 55, Pages S3-S16 (June 1999)

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer Mark A. Socinski, MD, Coleman Obasaju, MD, PhD, David Gandara, MD, Fred R.

IASLC 6th Latin American Conference on Lung Cancer

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Volume 51, Issue 5, Pages (May 2007)

Volume 134, Issue 6, (September 2008)

This Month in AJKD American Journal of Kidney Diseases

Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.

Friedrich Foerster, Peter Robert Galle JHEP Reports

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold Cancer Treatment Reviews Volume 59, Pages 54-60 (September 2017) DOI: 10.1016/j.ctrv.2017.04.007 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 Proposed algorithm for treatment decisions beyond the second line for metastatic colorectal cancer. BSC: best supportive care; ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; PD: progressive disease; WT: wild-type. Cancer Treatment Reviews 2017 59, 54-60DOI: (10.1016/j.ctrv.2017.04.007) Copyright © 2017 The Authors Terms and Conditions